DOJ Issues First Healthcare Fraud Declination, Sparing Company While Indicting Former CEO

When the U.S. Department of Justice unsealed a seven-count indictment against the founder of a New Jersey optometry practice on July 29, 2026, the charges themselves were standard fare for federal prosecutors: millions in alleged Medicare fraud and illegal kickbacks. But the true significance of the case lay not in who was charged, but in who was spared. In a landmark decision, the DOJ formally declined to prosecute the executive's company, Campus Eye Management, despite acknowledging that the corporate entity had benefited from the multi-year scheme.

The split decision marks the first time the DOJ has applied its newly revamped Corporate Enforcement Policy to a healthcare company, signaling a profound shift in how the government intends to police corporate fraud. By offering the company a clean slate in exchange for its cooperation, prosecutors have drawn a bright line between corporate entities that self-correct and the individual executives who orchestrate the crimes.[1][3]

The broader context of this decision is rooted in the sheer scale of the problem. Healthcare fraud is a massive drain on federal resources, and just weeks prior, the DOJ executed the 2026 National Health Care Fraud Takedown, charging hundreds of defendants in schemes involving billions of dollars.

Against this backdrop of aggressive enforcement, the Campus Eye declination stands out as a strategic pivot. The government is signaling that it cannot police the sprawling healthcare sector alone; it needs insiders to open their books and turn over the architects of the fraud.[5]

The mechanism driving this outcome is the Corporate Enforcement and Voluntary Self-Disclosure Policy (CEP), introduced by Acting Attorney General Blanche in March 2026. The CEP was designed to solve a persistent problem in white-collar enforcement: companies often hide internal misconduct because the financial and reputational costs of admitting guilt to the government are catastrophic. To break this cycle of silence, the CEP offers a powerful incentive known as a "declination"—a formal guarantee that the DOJ will not pursue criminal charges against the company.[1]

To earn this pass, a corporation must meet strict criteria. It must voluntarily self-disclose the misconduct before the government discovers it, fully cooperate with the ensuing investigation, remediate the compliance failures, and disgorge any ill-gotten profits. The Campus Eye resolution serves as the first public test case of this policy in the highly regulated healthcare sector, proving that the DOJ is willing to honor its end of the bargain if the company delivers the evidence required to prosecute culpable individuals.[3][5]

The allegations at the center of the Campus Eye case illustrate exactly the kind of entrenched fraud the DOJ is targeting. According to the indictment, E. Bruce DiDonato, the 71-year-old founder and former CEO of the practice, orchestrated a scheme that ran from 2015 until March 2023. Prosecutors claim DiDonato caused the company to bill Medicare and other private insurers for diagnostic eye tests that were either entirely unnecessary or duplicative of tests already performed.[1][4]

Crucially, the government alleges that neither DiDonato nor the referring physicians ever reviewed or relied upon the results of these tests for patient care. The tests existed solely as a vehicle to generate fraudulent billing codes, draining federal healthcare resources while providing no medical benefit to the patients subjected to them. This focus on medically unnecessary services has long been a priority for federal investigators, as it directly impacts both taxpayer funds and patient safety.[1]

To maintain the flow of patients required to sustain this billing operation, DiDonato allegedly relied on a sophisticated kickback network. The DOJ claims he paid bribes to referring ophthalmologists, ensuring a steady stream of surgical patients whose preoperative testing could be billed to Medicare. To conceal the illicit nature of these payments and evade the federal Anti-Kickback Statute, the bribes were allegedly disguised as monthly "flat fees" under sham consulting agreements.[3][5]

In reality, prosecutors argue, these payments were carefully pegged to the volume of Medicare reimbursements generated by each physician's referrals. Over the eight-year lifespan of the scheme, this arrangement allegedly resulted in approximately $3.7 million in fraudulent claims submitted to Medicare and other insurers. The indictment alleges that DiDonato even used the inflated revenues generated by this fraud to market and sell the practice to private equity investors at an artificially high valuation.[1][5]

The unraveling of the scheme highlights the critical role of corporate governance in modern healthcare compliance. In December 2021, outside investors acquired DiDonato's optometry practice and its affiliated ambulatory surgery center, forming Campus Eye Management Holdings LLC. DiDonato was retained as the CEO of the newly formed entity. However, as the new ownership group integrated the practice and implemented stricter compliance oversight, the irregularities in the billing and referral patterns came to light.[4]

In March 2023, the investors ousted DiDonato from his role as CEO and launched an internal investigation. Rather than attempting to quietly bury the findings, the new management team made the calculated decision to approach the DOJ, voluntarily disclosing the years of misconduct that had occurred both before and after their acquisition. Campus Eye's decision to self-report triggered the protections of the new CEP, but the declination required the company to engage in "full and proactive cooperation," including turning over evidence that directly implicated its former CEO.[3]

The financial resolution of the case further underscores the pragmatic approach embedded in the new DOJ policy. Under standard enforcement protocols, Campus Eye would have been required to disgorge the full $3.7 million in ill-gotten gains. However, the DOJ agreed to cap the disgorgement payment at $1 million after an independent "ability-to-pay" analysis concluded that forcing the company to pay the full amount would threaten its continued viability. By capping the penalty, the DOJ ensured that victims were compensated without destroying the cooperative corporate entity.[3]

While the company secured its survival, its former CEO now faces the full weight of the federal justice system. The seven-count indictment against DiDonato includes charges of conspiracy to commit healthcare fraud, conspiracy to violate the Anti-Kickback Statute, and multiple substantive counts of healthcare fraud.

If convicted, he faces a maximum penalty of 10 years in prison for each of the fraud counts. The stark contrast between the company's declination and the executive's indictment is the intended feature of the DOJ's strategy, ensuring culpable executives cannot hide behind the corporate veil.[1][2][4]

Legal analysts view the Campus Eye resolution as a watershed moment for corporate healthcare compliance, particularly for private equity sponsors. The case provides a predictable roadmap for how acquiring firms should handle the discovery of legacy fraud within their portfolio companies. Historically, investors might have hesitated to self-report out of fear that the resulting fines would wipe out their investment. The DOJ's willingness to grant a full declination and adjust disgorgement based on the ability to pay significantly alters that risk calculus, rewarding swift, transparent action.[4][5]

Looking ahead, the success of the Campus Eye prosecution will likely serve as a catalyst for further enforcement actions under the CEP. As healthcare companies digest the implications of this first-of-its-kind declination, the industry is bracing for a potential wave of self-reporting. For executives who have historically relied on corporate silence to protect their illicit schemes, the message from the DOJ is unambiguous: the very companies they lead are now financially incentivized to turn them in.[1][2]